共 140 条
[1]
Kearon C(2016)Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report Chest 149 315-352
[2]
Akl EA(2019)2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart R Circulation 140 e125-e151
[3]
Ornelas J(2015)National trends in ambulatory oral anticoagulant use Am J Med 128 1300-5.e2
[4]
Blaivas A(2016)Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry J Am Coll Cardiol 68 2597-2604
[5]
Jimenez D(2019)Effectiveness and safety of off-label dose-reduced direct oral anticoagulants in atrial fibrillation Am J Med 132 636-643
[6]
Bounameaux H(2020)Rates of potentially inappropriate dosing of direct-acting oral anticoagulants and associations with geriatric conditions among older patients with atrial fibrillation: the SAGE-AF study J Am Heart Assoc 9 50-37
[7]
January CT(2020)The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding J Thromb Thrombolysis 49 629-9
[8]
Wann LS(2009)Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science Implement Sci 4 4-124
[9]
Calkins H(2019)Survey of confidence in use of stroke and bleeding risk calculators, knowledge of anticoagulants, and comfort with prescription of anticoagulation in challenging scenarios: SUPPORT-AF II study J Thromb Thrombolysis 48 120-9
[10]
Chen LY(2018)Knowledge is power: general practitioners prescribing of new oral anticoagulants in Ireland BMC Research Notes BioMed Central 11 1-248